• Net revenue increased by 15 per cent to EUR 104.3m (91.0) with organic growth of 5 per cent
• Adjusted EBITA increased 3 per cent to EUR 25.4m (24.7) corresponding to a margin of 24.3 per cent (27.2)
• Operating profit (EBIT) of EUR 14.5m (13.2)
• Net result of EUR 8.6m (5.1) and earnings per share before and after dilution EUR 0.02 (0.01)
• Cash flow from operating activities of EUR 22.2 (5.9)

“Revenues for the second quarter grew 15 per cent to EUR 104.3 million at a margin of 24.3 per cent. Organic growth in the quarter was 5 per cent, negatively impacted by weak performance in our US MedTech orthopedics business. Our remaining three segments continued to deliver solid performance in the second quarter. In June, we completed the acquisition of AllAccem to expand and strengthen our veterinary dental offering”, says Carl-Johan Zetterberg Boudrie, interim CEO Vimian Group.

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://events.inderes.com/vimian-group/q2-report-2025/dial-in

To attend the webcast:
Link: https://vimian-group.events.inderes.com/q2-report-2025

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.